BMO Capital analyst Keith Bachman maintains UiPath (NYSE:PATH) with a Market Perform and lowers the price target from $29 to $21.
Mizuho Upgrades Douglas Emmett to Buy, Raises Price Target to $40
Mizuho analyst Omotayo Okusanya upgrades Douglas Emmett (NYSE:DEI) from Neutral to Buy and raises the price target from $32 to $40.